A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Infants With Type 1 Spinal Muscular Atrophy
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs RG 7916 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Therapeutic Use
- Acronyms Firefish
- Sponsors Roche
- 02 Oct 2017 Planned End Date changed from 1 Jul 2020 to 7 Jul 2020.
- 05 Sep 2017 Planned End Date changed from 30 May 2020 to 1 Jul 2020.
- 08 May 2017 According to a PTC Therapeutics media release, data from the first part of this study are expected to be presented at scientific meetings later this year (2017) and early 2018.